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Introduction
Prostate cancer (PC) is the second leading cause of male cancer death in the developed world [1] , however, the natural history of the disease is highly variable. Randomized controlled trials of global PSA screening for PC have demonstrated conflicting survival benefits [2, 3] , but significant evidence of overtreatment of this disease [2, 3] . Outcomes could be improved by distinguishing, prior to treatment, those at highest risk of developing metastatic disease versus men with clinically insignificant disease. Molecular biomarkers offer the potential for better risk assessment in PC. Although many putative biomarkers have been proposed in the literature, few have undergone validation and translation into clinical practice [4] .
Zinc-alpha 2-glycoprotein (AZGP1) is a 41-kDa soluble protein ubiquitous in most body fluids and in the secretory epithelial cells of many tissues, including the prostate [5] . Previous studies have identified the potential prognostic utility of AZGP1 in localized PC [6] [7] [8] [9] [10] [11] [12] where low AZGP1 expression may predict early biochemical relapse [7, [9] [10] [11] [12] . However, these were retrospective studies with biochemical rather than clinical endpoints, restricting their clinical application.
In the current study, we prospectively enrolled an independent phase III cohort to evaluate the clinical utility of AZGP1 as a biomarker in localized PC.
Methods

Study population
This was a prospective, multicentre phase III biomarker validation study. Patients were enrolled from seven urology practices across three major hospital districts in Australia between May 2007 and December 2012. Eligible patients had histologically proven adenocarcinoma of the prostate with radical prostatectomy (RP) planned as their primary treatment. Key exclusion criterion was androgen deprivation therapy prior to RP. Patients were recruited at the time of their primary surgery and consented to use of their RP specimen as well as their matched prostate biopsy specimen taken up to 5 months prior to surgery. The flow of patients through the study according to the REMARK criteria is shown in supplementary Figure S1 in Appendix S1, available at Annals of Oncology online.
The previous phase II cohort from our group was also re-analysed with updated follow-up [7] . An additional 56 patients from our retrospective consecutive patient cohort [13] who met the original inclusion criteria and with AZPG1 scores were included for analysis (supplementary Figure S1 , available at Annals of Oncology online).
The phase III study was approved by the St. Vincent's Research Ethics Committee (H07/025). All study participants provided written informed consent to tissue (prostate biopsy and RP) and data collection. The study was conducted in accordance with principles of the Helsinki Declaration.
Tissue microarray construction
Tissue microarrays (TMA) containing 1 mm cores of prostate adenocarcinoma were constructed from prospectively collected formalin-fixed paraffin-embedded RP tissue blocks as described previously [7] . Each patient was represented by a mean of four cores (range 1-5) in which each core was taken from the dominant cancer nodule [14] (supplementary Appendix S2, available at Annals of Oncology online).
Immunohistochemistry
Freshly cut TMA and prostate biopsy sections were immunostained with AZGP1 using an established protocol [7] (supplementary Appendix S2, available at Annals of Oncology online). Immunostaining was carried out at a NATA-accredited laboratory (Royal Prince Alfred Hospital, Australia).
Each prostate core from the TMA and prostate biopsy section were scored separately by independent investigators blinded to patient outcomes (AZ and JG). Both investigators reviewed discrepancies in scoring with a consensus score established. AZGP1 staining intensity was stratified into four categories (supplementary Figure S2 , available at Annals of Oncology online). For each case, the highest proportion of stained cells was considered the AZGP1 expression score. This score was then dichotomized with standardized cutpoints [7] [8] [9] [10] [11] : absent/low expression (0/1) and high expression (2/3), which was pre-defined by our phase II study prior to the phase III study [7] .
Statistical considerations
The primary endpoint was biochemical relapse-free survival (BRFS), measured from the date of RP to either the occurrence of biochemical relapse or date of last follow-up. Biochemical relapse was defined as confirmed PSA 0.2 ng/ml. Patients, who had disease recurrence (regardless of their salvage therapy), were censored at the time of recurrence. Secondary endpoints were metastasis-free survival (MFS) and PC-specific survival (PCSS) (supplementary Appendix S4, available at Annals of Oncology online).
We estimated that 311 patients would provide 80% power to detect a twofold increase in biochemical relapse rate (BRR) in a population with an overall relapse rate of 15% such that the data cut-off for analysis was 15% BRR (data-lock date was 15 April 2017). Accrual of at least 342 patients would allow for drop-out and missing data. AZGP1 expression levels and other variables were evaluated as predictors of disease relapse using the Kaplan-Meier method, and by univariable and forward-conditional multivariable analyses in Cox proportional hazards models. Variables were selected for the multivariable model based on the established variables of PC relapse [15] . Harrell's concordance index was used to measure the predictive discrimination of models for timedependent outcomes [16] . The Spearman correlation coefficient was used to assess the correlation between AZGP1 scores from the prostatectomy TMAs and their matched prostate biopsies. The core-to-core reproducibility of the AZGP1 scores was expressed as an intra-class correlation coefficient for each observer. All reported P-values were two-sided. Statistical analyses were carried out using IBM SPSS Statistics, version 23 and somersd package in STATA/SE (version 9.2). Our findings are reported based on the REMARK guidelines [17] .
Results
The expanded phase II cohort included 284 patients enrolled between 1986 and 1999 [7] . For the phase III study, 427 patients were prospectively recruited. Of these, we were able to obtain adequate tissue blocks and comprehensive follow-up data for 347 patients.
The clinicopathological characteristics for both cohorts are outlined in Table 1 . Patients in the phase II cohort were treated in the pre-PSA screening era prior to 1995. In the phase III cohort, pre-operative PSA, ISUP Grade Group score, extra-prostatic extension (EPE), seminal vesicle invasion (SVI), positive surgical margins and pathological stage (P-stage) were predictors of BRFS on univariable analyses (Table 2 ; supplementary Figure S3 , available at Annals of Oncology online). ISUP Grade Group score, EPE, SVI and P-stage were predictive of MFS (Table 2 ; supplementary Figure S4 , available at Annals of Oncology online).
AZGP1 in the updated phase II cohort
In the updated phase II cohort, AZGP1 expression data were available on 284 patients with 80/284 (28%) being absent/low. At a median follow-up of 15.8 years (0.5-28 years), the phase II cohort had 198 (70%) biochemical relapses, 34 (12%) metastatic relapses and 23 (8%) PC deaths. Men with low/absent AZGP1 expression had a shorter median BRFS (25 versus 40 months; P ¼ 0.01) ( Figure 1A and Table 2 ). On multivariable analysis, only AZGP1 and ISUP grade group were significantly associated with BRFS (AZGP1: HR, 1.4; 95% CI, 1.0-1.9; P ¼ 0.03; Table 2 ).
The original report of the phase II study was the first of its kind to show an association between AZGP1 and metastatic relapse in PC [7] . With extended follow-up and inclusion of additional patients, we confirm that absent/low AZGP1 expression is associated with poor MFS in the univariable (HR, 3.4; 95% CI, 1.7-6.8; P < 0.001) and multivariable models (HR, 2.8; 95% CI, 1.2-6.6; P ¼ 0.02; Figure 1B and Table 2 ). In the phase II cohort, absent/ low AZGP1 is also an independent predictor of PCSS when modelled with ISUP Grade Group (HR, 3.8; 95% CI, 1.5-9.5; P ¼ 0.005; Figure 1C and Table 2 ).
AZGP1 in the phase III cohort
In the phase III cohort, 6% (20/347) of patients had absent, 23% (80/347) weak, 61% (214/347) moderate and 10% (33/347) strong AZGP1 expression. The core-to-core heterogeneity was assessed using the intra-class correlation coefficient (ICC). The ICC for AZGP1 for observer 1 was 0.792 (95% CI, 0.742-0.832), and for observer 2 was 0.863 (95% CI, 0.732-0.942). This indicates that AZGP1 expression in the cores for the individual patients were in strong agreement. The inter-observer concordance between the two independent observers using Spearman's correlation was high at 88%.
At a median follow-up of 6.4 years (range 0.3-9.3), 55/347 (16%) patients in the phase III cohort had a biochemical relapse. Absent/weak AZGP1 expression was associated with poorer BRFS ( Figure 1D and Table 2 ). Median BRFS was lower in patients with absent/weak AZGP1 expression (56 versus 70 months; Figure 1D ). AZGP1 remained an independent predictor of BRFS when modelled with pre-operative PSA, ISUP Grade Group, P-stage and margin status (HR, 1.9; 95% CI, 1.1-3.3; P ¼ 0.02; Table 2 ).
The metastatic relapse rate in the phase III cohort was 18/347 (5%). Absent/low AZGP1 expression was significantly associated with a higher rate of metastasis (HR, 2.0; 95% CI, 1.1-3.4; P ¼ 0.02; Figure 1E and Table 2 ). At the time of analysis, there were 5(1%) PC deaths in the phase III cohort. Absent/low AZGP1 expression was associated with poorer PCSS on univariable analysis (HR, 10.0; 95% CI, 1.1-89.7; P ¼ 0.03; Figure 1F and Table 2 ). Multivariable analysis was not carried out for PCSS due to the limited number of events.
AZGP1 and prognostic models
We demonstrate that adding AZGP1 to existing prognostic models for BRFS, MFS and PCSS improves risk modelling in PC. The fivestratum risk model proposed by Gnanapragasam et al. was compared with the NICE risk stratification system and demonstrated improved predictive power in determining PCSS [18] . A second prognostic model, the CAPRA-S score, compares favourably with other nomograms for prediction of BRFS after RP [19] .
Using the phase III cohort, the Gnanapragasam stratification system (GSS) has a concordance-index (C-index) for predicting BRFS of 0.736 (95% CI, 0.673-0.799). Incorporating AZGP1 into this risk model improves the C-index to 0.758 (95% CI, 0.697-0.819). Moreover, AZGP1 improves the discriminatory accuracy of the GSS for predicting MFS and PCSS; AZGP1 combined with GSS improved the C-index from 0.788 (95% CI, 0.681-0.892) to 0.814 (95% CI, 0.725-0.900) for MFS, and 0.683 (95% CI, 0.432-0.954) to 0.756 (95% CI, 0.567-0.944) for PCSS (Table 3) .
Similarly, in our phase III dataset, the CAPRA-S predicted BRFS with a C-index of 0.748 (95% CI, 0.685-0.812). AZGP1 modestly improves this C-index to 0.765 (95% CI, 0.704-0.827). The addition of AZGP1 to the CAPRA-S score consistently improves the C-index for prediction of MFS and PCSS (Table 3 ).
AZGP1 expression in prostate biopsies
In the phase III cohort, the pre-operative prostate biopsy specimens were available for 227/347 (65%) of cases. There was no correlation between pre-treatment prostate biopsy and RP-based AZGP1 scores (P ¼ 0.13). Biopsy AZGP1 score did not predict for BRFS or MFS (supplementary Figure S5 , available at Annals of Oncology online).
Discussion
To our knowledge, this is the first prospective multicentre phase III study of AZGP1 in PC. It demonstrates that absent/low [7, 9, 10, 12, 20] . The reproducibility of these findings in our prospective study, demonstrates that AZGP1 is a robust prognostic biomarker for biochemical disease-free outcome. However, localized PC, irrespective of therapy, has a rate of cancer-specific mortality of <2% [21] and biochemical relapse is not a surrogate for lethal disease.
Our study is unique in showing that low/absent AZGP1 expression is also associated with metastatic relapse in both cohorts.
A recent meta-analysis demonstrated that MFS is a robust surrogate for overall survival in localized PC [22] . Despite low event numbers, AZGP1 was also associated with PCSS. AZGP1 biomarker status consistently improves the discriminatory value for BRFS, MFS and PCSS when added to existing post-RP PC prognostic models [18, 19] . Together, these findings confirm that AZGP1 expression can identify clinically relevant localized PC in whom treatment may change the natural history of the disease.
Throughout this study, we worked towards the goal of implementation. We carried out AZGP1 staining in a NATAaccredited laboratory with two independent observers of AZGP1 in order to reduce bias of personal interpretation and assess inter-observer variability. In doing so, we determined that scoring of this biomarker is highly reproducible and concordant between observers. Studies show that TMAs are robust sampling strategies for the identification of clinical biomarkers in PC particularly when 4 samples are used for each cancer [23] . Appreciating that there may be within-tumour differences in staining intensities, our study also demonstrates the core-to-core heterogeneity of AZGP1 is low. Thus we would propose that in the clinical setting, a single section from the dominant nodule showing >50% cancer cells with absent/low AZGP1 would be sufficient to place patients in a poor prognostic category.
There is clinical evidence that the relative loss or absence of AZGP1 is implicated in the progression of PC from localized to metastatic disease. AZGP1 is physiologically expressed in various normal tissues, including breast and prostate [5] . The gene expression of AZGP1 is predominantly regulated by androgens with increased expression of AZGP1 mRNA in the LNCaP cell line under androgen exposure [24, 25] and the presence of androgen response elements in the promoter region of the AZGP1 gene [25] . The repressor element-1 silencing transcription factor has been shown to limit expression of androgen-regulated genes in PC cells, including AZGP1 [26] . AZGP1's role in PC may also be intrinsically related to the interplay between cancer progression and lipid metabolism [27] . Serum AZGP1 is associated with insulin resistance [28] . These mechanisms are poorly defined, however, obesity and insulin resistance have both been implicated in prostate carcinogenesis and progression [29, 30] . Our group has previously determined an inverse relationship between GATA-2 and AZGP1 expression in vitro, a process that may be related to GATA-2's role in the de-differentiation of adipocytes [25] . Clearly, additional work is required to better define the biological role of AZGP1.
The ideal molecular prognostic marker for localized PC would be one that could predict outcome at biopsy and help inform the decision to proceed to localized therapy. With this in mind, we assayed both pre-operative prostate biopsies and RP specimens. However, there was no concordance between AZGP1 scores based on biopsies compared with AZGP1 scores on RP specimens and no significant relationship between biopsy AZGP1 expression and outcome. This may have been secondary to sampling error as only 227/347 matching prostate biopsy specimens were available in our study. However, a more likely explanation is sampling bias related to the pre-operative biopsies themselves. Concordance between Gleason score at biopsy and at RP ranges from 59% to 94% [31] . Thus, it is likely that a molecular result from a single pre-operative biopsy could not cover the heterogeneity of expression in the same way as multiple cores in a TMA from a RP specimen. Therefore, AZGP1 scores from preoperative biopsies cannot be used at this time to predict those who may or may not benefit from surgery.
Conclusion
Our study demonstrates that AZGP1 is a reproducible predictor of biochemical and metastatic relapse in patients with localized PC treated with RP. Data from our prospective phase III cohort suggest that AZGP1 should now become part of clinical pathology practice. 
